Summary.-Tumour antigen-induced inhibition of leucocyte adherence was modified for use in glass test tubes (Tube LAI assay) for the study of cell-mediated antitumour immunity to human malignant melanoma. Peripheral blood leucocytes (PBL) of 20 out of 25 patients (80%) with active malignant melanoma responded to an extract of malignant melanoma with LAI, whereas only 4.5%o of 475 control subjects showed a response. The malignant melanoma patients reacted to both allogeneic and autologous extracts of malignant melanoma which indicates a common cross-reacting antigen. Malignant melanoma patients did not respond to unrelated tumour extracts. The LAI was mediated by PBL (monocytes) " armed" with cytophilic anti-tumour antibody specific for the sensitizing tumour antigen.
responses to tumour are observed with tumour progression (Lewis et al., 1969; Morton, Eilber and Malmgren, 1971; deVries et al., 1972; Cochran et al., 1973; . Halliday and Miller (1972) developed an assay of cell-mediated anti-tumour immunity, called leucocyte adherence inhibition (LAI). This assay is based on the findings that non-sensitized leucocytes from both patients with cancer and control subjects adhere to glass, whereas leucocytes from cancer patients but not from control subjects, when mixed in vitro with antigenic extracts of tumours of the same histologic type, undergo a diminution in their normal adherence to glass surfaces. In a rat model, Holan et al. (1974) described a modified version of the LAI assay that was performed in test tubes and the number of non-adherent cells was measured. We modified the LAI procedure of Holan et al., and studied the antitumour immunity to human breast cancer (Grosser and Thomson, 1975) .
Recently Halliday et al. (1975) reported the results of the LAI assay in 75 patients with malignant melanoma. We studied LAI in 33 patients with malignant melanoma by the LAI assay in test tubes (Tube LAI assay), an assay that appears to differ only methodologically. Nevertheless, there are important differences in the results in the two studies. In the present study we show that LAI depends on the extent of the malignant melanoma, and patients with large tumour loads were unreactive. In addition, surgery and chemotherapy altered LAI. Furthermore, when the kinetics of LAI were monitored during the year after excision of the primary melanoma, LAI reactivity was generally undetectable 6-8 months post-surgery in "cancer-free" patients.
MATERIALS AND METHODS
Subject studies-.Heparinized blood samples were obtained by venepuncture from 33 patients with malignant melanoma.
Thirty patients had cutaneous melanoma and 3 patients had ocular melanoma (one primary and 2 secondary). The In some instances, patients with Stage I melanoma were assayed after punch biopsy of the suspect skin lesion, but always before definitive wide surgical excision and skin grafting. Patients with Stage II melanoma were assayed prior to complete surgical excision of the malignant melanoma. Patients with Stage III melanoma had previously had their lesion excised and were presenting with recurrent tumour when they were assayed. In addition, there were 8 patients who had had a cutaneous malignant melanoma (Stage I or II) excised at least a year earlier and they were clinically cancer-free when they were tested for the first time.
All subjects who gave blood samples had the nature of the test explained to them and verbal consent was obtained.
Tumour extracts.-Malignant melanoma samples were received at operation and placed in a sterile container. Appropriate amounts of the tumours were taken for routine pathology. Fatty and fibrous tissues were dissected away, and the specimen was finely minced with sharp scissors in ice-cold PBS (001 M phosphate buffer, 0415 M saline) at pH 7-3. The resulting material was homogenized for 10-15 min in 5 volumes of PBS at 40,000 rev/min in a Virtris 45 homogenizer. The homogenate was centrifuged at 20,000 g for 30 min and the supernatants were stored at -40°C in 2-ml aliquots. Extracts of other tumours were prepared in an identical fashion. The protein concentrations of the stock extracts of malignant melanoma, breast cancer, and other tumours were 6-8-5 mg/ml. All tumour extracts were of similar protein concentrations. LAI assay in test tubes was performed with a stock extract composed of a pool of 3 different melanoiiia tumour extracts, whereas individual breast or bladder tumour samples ere employed as the non-specific control extracts.
For use in the assay, the concentrated stock extracts were thawed in a water bath at 20°C and a sample was diluted with Medium 199 (Gibco, Grand Island, N.Y.) . An 0'1-ml aliquot of the diluted stock extract was added to certain designated tubes containing the standard quantity of 106 PBL in 0-1 ml of Medium 199. Antigen-idnduced leucocyte adherence inhibition (LAI) to glass in test tubes (Tube LAI assay). The LAI assay in test tubes was performed as previously described by Grosser and Thomson (1975) . In brief, 20-ml samples of heparinized venous blood were obtained in tw o 10-ml green stopper vacutainer tubes (Beeton, Dickinson & Co., Mississauga, Ont.) and incubated vei-tically at 37°C for 1 h. The r-esulting leucocyte-rich plasma fraction was aspirated and centrifuged at 200 9 for 5 min. The cell-free plasma was then removed and discarded. 'T'he cell button as suspended in an ice-cold, isotonic, Tris-buffered NH4C1 solution (Boyum, 1968) Since this aspect of the study involved delineating the reactivity of patients to malignant melanoma, the specific antigen was an extract of malignant melanoma, while the unrelated antigens were extracts of breast cancer and bladder cancer. Extracts of other tumours, such as cancers of ovary, bladder and lung, were prepared in a similar manner and also employed as the nonspecific control antigen or for the study of the specificity of LAI.
Titration of tumour extracts. The stock tumour extracts were diluted and added to the test tubes at different protein concentrations. Figure 1 shows that protein concentrations of approximately 110 ,tg and 120 ,ug for malignant melanoma and breast tumour extracts respectively appear to be optimal. The tumour extracts were used throughout this study at these dilutions. In this study, other tumour extracts were used at approximately 100 ,ug protein/test tube. Protein determinations were performed by the method of Lowry et al. (1963) using bovine serum albumin as a standard. ' Arming " of control cells by serun fromn reactive melanoma patients.-Blood was taken from melanoma and breast cancer patients and control subjects and immediately stored at 4°C. After overnight retraction of the clot, the serum was separated and stored at -400C.
Patients with Stage I or Stage II malignant melanoma and breast cancer had their serum assayed for ' arming" in the LAI assay. Before use, the serum was diluted llX 1 1 w Nith Medium 199, and 0 5 ml of the above solution was added to 107 PBL from healthy control subjects, suspended in 0 5 ml of Medium 199. The mixture was then incubated for 45-60 min at 37°C in 50o CO2 atmosphere with intermittent shaking of the tubes. At the end of this period, the cells were spun dow,n, washed 3 times with Medium 199 and then plated separately in test tubes with Medium 199 alone, breast cancer and melanoma extracts. PBL from healthy subjects were also tested in the LAI assay after incubation with 199 alone, with serum from control subjects and from patients with metastatic disease who were non-reactive.
Serum IgG was isolated by the batch method of Reif (1969) with DEAE cellulose.
Thie purity of the isolated IgG was examined by immunoelectrophoresis with anti-wholehuman serum.
RESULTS

Specificity of LAI in test tubes
When PBL from malignant melanoma patients or control subjects are incubated in glass test tubes without antigen for 2 h, (Table I) . Similarly, the addition of tumour extract to non-sensitized PBL inhibited the adherence of 18-38%0 of the leucocytes and the number of non-adherent leucocytes increased with the more concentrated tumour extract (Table I and Fig. la, b) . and the reactive cell was a peripheral blood monocyte (Grosser and Thomson, 1975; (Table VII) . Clinical features of LAI in test tubes in (Table VIII) . In this series of patients and malignant melanoma with these tumour extracts, NAI > 30 The results in 33 patients with histo-was selected as significant on the basis logically proven malignant melanoma are that this value best separated the populashown in Fig. 2 Figure 2 shows that all patients had a marked fall in their NAI to melanoma extract in the first and second postoperative week. In general, patients showed a recovery of their LAI to melanoma extract (Fig. 4) . Not shown in Fig. 4 (Fig. 4) (Fig. 6 ). After recovery of LAI, treatment of the patient with DTIC chemotherapy depressed the leucocyte response to melanoma antigen as assessed by the tube LAI assay (Fig. 6) Table IX shows that the leucocytes of a reactive melanoma patient reacted to the ascitic fluid and to the melanoma extract, suggesting that the ascitic fluid from the melanoma patient contained either particulate or soluble melanoma antigen.
DISCUSSION
The results of this study indicate that the LAI assay, modified for use in glass test tubes (Tube LAI assay), is a simple and quantitative method for measuring anti-tumour immunity to malignant melanoma. In agreement with the study of Halliday et al. (1975) , the tube LAI assay for malignant melanoma appears to be immunologically specific and reproducible. Peripheral blood leucocytes of 20 out of 25 patients (80%) with active malignant melanoma responded to an extract of malignant melanoma with significant leucocyte adherence inhibition, whereas 4*5 00 of control subjects showed a response. Anti-tumour immunity to the malignant melanoma antigen as measured by LAI was depressed by surgery and chemotherapy. In contrast to the report of Halliday et al. (1975) , melanoma patients with a large tumour load exhibited diminished or no LAI; moreover, in "tumour-free " patients LAI to malignant melanoma extract was not detectable 6-8 months after excision of the tumour.
The tube LAI assay is performed in serumless medium. Koller et al. (1973) showed that the majority of mononuclear cells that adhere to glass or plastic, in the absence of serum, are lymphocytes. Both membrane markers and mitogen response indicate that these lymphocytes are a mixture of B and T cells. In the present study we also observed that the majority of buffy coat PBL adhered to the glass in the absence of serum (protein). Leucocytes from control subjects showed non-specific non-adherence with the addition of tumour extracts, and the number of non-adherent cells (00 nonadherence) was Lewis et al. (1969) showed, by indirect membrane immunofluorescence, that serum from melanoma patients reacted against the autologous melanoma cell surfaces and lacked significant crossreactivity with allogeneic melanoma. Bodurtha et al. (1975) , by a complementdependent cytotoxicity assay for antibodies to malignant melanoma, confirmed the findings of Lewis et al. (1969) . Other investigators, however, have shown crossreactivity with membrane immunofluorescence and cell-mediated assays (Morton et al., 1968; Currie et al., 1971; Nairn et al., 1972; and Hollinshead et al., 1974) .
In the present study, it was shown that serum from patients whose leucocytes were reactive in the assay could " arm " normal PBL to the appropriate tumour extract. The serum factor was IgG antibody. Moreover, in other studies have shown that the reactive cell is phagocytic, glass-adherent in the presence of serum and absence of antigen, and has Fc cell-surface receptors. Hence the LAI phenomenon is mediated by peripheral blood monocytes " armed" with cytophilic anti-tumour antibody.
The results of the present study indicate that the anti-tumour immune response of the malignant melanoma patient was dependent on the extent of the cancer, whereas Halliday et al. (1975) have not reported any variation in LAI with extent of disease. Patients with cancer confined to the primary site had strong responses and 11 out of 13 patients had a positive NAI. Patients with regional lymph node involvement (Stage II) appeared to have an equally intense and, in a few instances, even more intense LAI. Patients with widely disseminated melanoma to the viscera had a markedly impaired anti-tumour immune response and 3 out of 5 patients had a negative NAI. One of the 2 reactive patients with Stage III cancer initially had a minimal tumour burden and, as the tumour burden increased, showed a loss of reactivity. By other in vitro assays of CMI or humoral immunity, a diminution of tumour-specific immunity in melanoma patients with disseminated disease has been reported (Morton et al., 1968; Lewis et al., 1969; Currie and Basham, 1972; Cochran et al., 1973; Heppner et al., 1973; and Unsgaard and O'Toole, 1975 Coggin et al., 1974) . We suggested that soluble tumour antigen in the microenvironment of the tumour prevents rejection (Thomson, 1975) and, as the tumour load increases, sufficient tumour antigen is released systemically to neutralize systemic anti-tumour immunity. In the present study, this hypothesis was supported by the finding that particulate or soluble melanoma a,ntigen was present in the tissue fluids surrounding peritoneal metastasis.
Melanoma patients had their LAI monitored before and after surgical excision of their tumour. LAI was profoundly depressed during the first 2 weeks after surgery. In a previous paper, we reported the depression of LAI after operation in breast cancer patients (Grosser and Thomson, 1975) . Slade et al. (1975) showed that many aspects of the immune system are depressed by surgery, and Cochran, John and Gothoskar (1972) reported that all melanoma patients had reduced specific tumour immunity postoperatively as measured by macrophage migration inhibition, and reactivity returned in most cases 6-22 days after (Engell, 1959; Griffiths et al., 1973) . In an experimental animal tumour model, Eccles and Alexander (1975) Although their mean NAI of 22 was below the cut-off value of 30, it was higher than the mean NAI of the control subjects.
WNrith their assay Maluish and Halliday (1 974) and Halliday et al. (I1975) have noted no change in LAI in cancer-free" patients during the year after tumour excision. In the micro-cytotoxicity assay, O'Toole et al. (1973) and Unsgaard and O'Toole (1975) observed that removal of tumours by surgery resulted in a loss of detectable CMI in tumour-free patients even one month after surgery, whereas reported that the majority of clinically cured patients had tumour-specific CMI during a 1-2-year observation period after surgery.
Although LAI diminished after 6-8 months in tumour-free patients, the pattern of LAI in those patients who eventually manifested recurrent cancer showed 2 different patterns. In one instance, LAI remained elevated 11 months after " curative " surgery and fell shortly before clinical evidence of widespread visceral metastasis. The other pattern showed a fall in LAI, similar to that in patients who remained cancer-free, with a, rise in LAI slightly before local or limited visceral recurrence. Holan et al. (1974) and Grosser and Thomson (1975) reported that the addition of serum directly in the tube LAI assay either had a non-specific effect or no effect at all. By contrast, Halliday et al. (1975) and Maluish and Halliday (1974) have reported that serum from early and late tumour-bearers " blocks " the assay, and serum from " cured " patients is frequently unblocking". We have found that, by pre-incubation of normal leucocytes with serum from reactive patients with melanoma or breast cancer, and washing the cells before plating them in the tube LAI assay, immunologically specific " arming " can be detected. These results are different from those of Halliday et al. (1975) in that serum from patients reactive in the assay can " arm " normal leucocytes, and serum from metastatic unreactive patients does not " arm ". Moreover, serum from nonreactive melanoma patients with large tumour burdens can " block " the reactivity of leucocytes from reactive melanoma patients in the tube LAI assay . The blocking is immunologically specific and therefore indicates that free antigenic determinants must produce the effect, since immune complexes bind to lymphocytes annd monocytes non-specifically.
The LAI assays performed on haemocytometers (Hallidav and Miller, 1972) and in test tubes (Holan et al., 1974; Grosser and Thomson, 1975) appear to differ only methodologically; nevertheless, important differences in the results are observed. Holan (1975) has also observed a weaker LAI in rats with large progressively growing tumours than in rats with small regressing tumours.
The explanation for the difference in results is not readily apparent but may be related to the difference in incubation conditions.
The ease and rapidity of performing the tube LAI assay and its reproducibility make it useful to monitor the antitumour immune response. The changes observed in PBL reactivity in the LAI assay have diagnostic potential when correlated with detailed clinical knowledge of the patient. Moreover, since the changes in LAI reflect the patient's clinical status, the need for performing blocking and unblocking studies is less necessary. This is important, since a constant source of reactive leucocytes is frequently neither available nor practical.
